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The relevance of the malignant pleuric 
mesothelioma (MPM) biomarkers
MPM is a highly aggressive tumor with a poor survival 
rate (1).
It is characterized by a long latency period in spite of its 
rapid, aggressive clinical outcome.
Therefore, effective preventive protocols may include 
very frequent instrumental diagnostic tests performed over 
a long period of time, i.e., decades, which may be neither 
economic nor ethical. Consequently, the use of early 
high sensitivity/specificity diagnostic markers is strongly 
recommended.
For screening and early diagnosis of MPM, new tools are 
necessary, and several biomarkers have been suggested (2).
Presently, there are no useful tools for screening and 
early diagnosis of MPM, while clinical monitoring is 
based mainly on radiological tests. Moreover, evaluation 
of therapy response in MPM remains difficult, especially 
because of poor sensitivity and operator dependency of 
radiological assessment (3). In addition, in most cases 
relapse is characterized by a very rapid time course.
Several MPM biomarkers have been studied and some 
of them are still under investigation, these researches 
investigate serum, plasma and pleural effusions, especially 
using ELISA (4).
The value of tumor markers is more available to the 
clinician: it can only be useful if required and interpreted 
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taking into account the other information available to the 
clinical context.
An incorrect interpretation can trigger a series of 
diagnostic insights, even invasive, with stress and expenses 
that may not be justified.
Soluble mesothelin-related peptides (SMRP)
Mesothelin originates as a precursor of 71-kDa, then cutted 
into two mature proteins: megakaryocyte potentiating 
factor (MPF), secreted into the blood, and a cell surface 
glycoprotein (MW approximately 40 kDa) recognized 
by Chang and Pastan on 1992 in ovarian carcinomas (5), 
and then in malignant mesotheliomas, squamous-cell 
carcinomas and normal mesothelial cells (6).
SMRP are potentially a tumor marker for MPM. Many 
studies aimed to determine the differences in SMRP levels 
in patients with MPM versus patients with benign pleural 
disease or lung cancer (LC) or individuals formerly asbestos 
exposed; in other cases in patients with MPM before and 
after treatment.
Determination of serum SMRP has been proposed 
on 2003 by Robinson et al. as a marker for diagnosis of 
mesothelioma and monitoring disease progression on a 
relatively small group of subjects (7). Yet, SMRP dosage has 
been suggested to be a useful tool for screening asbestos-
exposed individuals for early evidence of MPM and, 
possibly, LC.
Other studies (8-14) confirmed that serum SMRP was 
a promising marker for diagnosis, prognosis and clinical 
monitoring of MPM. High SMRP concentrations were 
detected in all the studies only in the epithelioid and mixed 
MPM.
Our data, in particular, provide the evidence that 
high SMRP dosage can be considered as an independent 
prognostic tool for patients with epithelioid MPM and 
suggest that this dosage could be useful both as a screening 
test for diagnosis (11), interpreted, of course, taking into 
account the other information available to the clinical 
context.
An important Individual patient data meta-analysis was 
performed by Hollevoet et al. (15). In symptomatic or high-
risk individuals, this meta-analysis showed that a negative 
blood test for SMRP does not exclude MPM, even at a 
high-sensitivity threshold. On the contrary, a positive blood 
test for SMRP at a high specificity threshold leads to further 
diagnostic steps and could possibly help an earlier diagnosis.
The low false positivity indicated a high specificity as 
well. The detection of elevated SMRP levels in asbestos-
exposed subjects should induce the clinical consideration 
of the presence of MPM denotes. A lower probability of 
the presence of MPM in patients with normal SMRP levels 
can be considered due to the high negative predictive value 
of the method, but the limiting lower sensitivity cannot 
entirely excluded the presence of disease (16).
Several findings suggest that SMRP may be a useful 
tumor marker for detecting the progression of malignant 
mesothel ioma and evaluat ing tumor response to 
treatment (17).
However, the poor sensitivity of mesothelin (35–50%) 
limits its value for diagnosis (18).
Osteopontin (OPN)
OPN is a secreted glycoprotein that plays key roles in 
different biological processes, such as immunological 
regulation, cell-matrix interaction, cell migration and tumor 
development (19,20). The circulating OPN levels in serum 
are increased in several cancers, including MPM (21), 
in which serum OPN has been considered as a potential 
biomarker for early detection of the disease (22,23).
Our data suggest that confounding factors such as age, 
smoking habits and asbestos exposure do not influence 
plasma OPN and serum OPN. In addition to traditional 
radiological exams, plasma and serum OPN may be useful 
markers in the diagnosis of epithelial MPM. Furthermore, 
plasma OPN is more stable than serum OPN, and 
measurements of OPN in plasma are more reliable (23,24).
Other authors confirmed OPN as an effective marker 
for MPM diagnosis (22,25-28) and the utility as biological 
markers for the health surveillance of past-exposed 
patients (28). Nevertheless, further studies with a larger 
sample size and better design are needed to carefully assess 
the diagnostic power of this biomarker (25).
Fibulin-3
Human fibulin-3 is a secreted glycoprotein encoded by 
the epidermal growth factor (EGF)-containing fibulin-like 
extracellular matrix protein-1 (EFEMP-1) gene (29), and it 
could play a role in the regulation of MPM cell proliferation 
and migration. Fibulin-3 is produced in MPM but its role 
remains uncertain (30).
Several studies have investigated the diagnostic value of 
fibulin-3 for MPM and based on these fibulin-3 results a 
useful diagnostic marker for MPM (30-34).
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Plasma fibulin-3 levels can distinguish healthy persons 
with exposure to asbestos from patients with mesothelioma. 
In conjunction with effusion fibulin-3 levels, plasma 
fibulin-3 levels can further differentiate mesothelioma 
effusions from other malignant and benign effusions (31).
Creaney et al. determined that fibulin-3 is increased 
in the plasma of MPM patients but at a lower diagnostic 
sensitivity than previously reported and inferior to that of 
SMRP in both plasma and effusions (32).
Other authors considered that the real use for serum 
fibulin-3 was for diagnosis in MPM but not for prognosis (30).
MicroRNAs (MiRNAs)
MiRNAs are short RNA no-codifing sequences. In recent 
years, miRNAs expression involved in post-transcriptional 
regulation of gene expression-in mesothelioma biology 
was found dysregulated both in cancer cells and sera, 
in patients affected by tumors of different histotypes, 
including MPM (35).
MiRNA are recently considered as diagnostic markers 
in different types of cancer. Preliminary analysis evidence 
miRNAs as possible markers for diagnosis and prognosis of 
MPM, and hypothesize new mechanisms for the therapy of 
this malignancy (35-48). 
The histopathological subtypes were associated with 
the expression of miR-17-5p, miR-21, miR-29a, miR-30c, 
miR-30e-5p, miR-106a, and miR-143 and the reduction of 
the expression of two miRNAs (miR-17-5p and miR-30c) 
correlated with better survival of patients with sarcomatoid 
subtype (37).
Gee et al. studied the molecular differences between 
mesothelioma and lung adenocarcinoma by using miRNA 
microarrays (36).
Santarelli et al. proposed miR-126 as useful marker 
because significantly remained down-regulated in the 
malignant tissues compared with the normal tissues (38) and 
in serum (41) while Kirschner et al. confirmed the potential 
of miR-29c and miR-92a as candidate tumor markers and 
revealed that miR-625-3p was a promising novel diagnostic 
marker for MPM (39).
Bononi et al., on the base of their studies, proposed 
as potential new MPM biomarkers three circulating up-
regulated microRNAs, i.e., miR-197-3p, miR-1281 and 
miR-32-3p (35).
M i c o l u c c i  e t  a l .  d e s i g n a t e d  a s  “ m e s o m i R s ” 
(MM-associated miRNAs), a pool of deregulated circulating 
and tissue miRNAs; identified as biomarker useful for 
MPM.
Data from previously exposed to asbestos and MPM 
subjects showed that the most promising candidates for 
a multimarker signature were circulating miR-126-3p, 
miR-103a-3p, and miR-625-3p in combination with 
SMRP (44).
De Santi et al. showed that in MPM the pattern of 
miRNAs expression is highly deregulated and that a 
2-miRNA signature (Let-7c-5p and miR-151a-5p) can be 
considered as a useful tool for prognosis of MPM (45). Also 
miRNA-16 was directly related to MPM patient prognosis, 
suggesting its possible use as a prognostic marker in MPM 
patients (47).
The study of Cavalleri et al. suggests that plasmatic 
extracellular vesicles (EV)-associated miR-103a-3p and 
miR-30e-3p are able to discriminate MPM from subjects 
with past asbestos exposure (46).
Standardized validation studies are needed to assess 
clinical relevance of the MiRNAs, so as to move from the 
workbench to the clinic (44).
For screening use as biomarkers for monitoring 
of workers exposed to asbestos a better knowledge of 
miRNA signatures in MPM is still necessary to verify 
the contribution of specific miRNAs as early diagnostic 
biomarkers, also compared to different asbestos forms, 
exposure and subject work history (42).
Other biomarkers proposed
Many other indicators have been evaluated as biomarker for 
MPM [cytokines, serum thioredoxin-1 (TRX-1), CA125, 
CYFRA 21-1, IL6, HGF, desmin, IP10, vimentin, THSP2, 
circulating fibrinogen, etc.].
MPF is a 31-kDa secreted cytokine, originated from 
mesothelin cutting. When evaluated in serum of MPM 
patients and control subjects by ELISA, MPF levels were 
higher in MPM cases, with respect to healthy subjects, 
individuals with benign asbestos-related diseases, or LC 
patients (49,50).
C-C chemokine RANTES were found significantly 
associated with workers formerly asbestos exposed and 
MPM patients compared with healthy controls. Increased 
immune mediator concentrations were observed in the sera 
of the workers previously exposed to asbestos compared 
to controls for human fibroblast growth factor (FGF-b), 
vascular endothelial growth factor (VEGF), CCL5 
(RANTES), CXCL10 (IP-10), CLEC11A (SCGF-b), 
CCL27 (CTACK), CCL11 (EOTAXIN), IL-5 and IL-6 
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(P<0.001). Levels of chemokines IP-10 and RANTES were 
associated with the severity of asbestos-related diseases. 
The immune proteins secreted by mesothelioma biopsies 
showed detectable levels of RANTES, VEGF, and IP-10 
in MPM patients. A significant relationship between serum 
and pleural fluid concentrations was found for RANTES 
alone in the MPM cases (51).
In the progression of asbestos-related diseases some 
chemokines may have a prognostic role and can be useful 
for the health surveillance of workers with an occupational 
history of asbestos exposure, and patients affected by non-
malignant asbestos-related diseases (52).
To differentiate patients with MPM from SPE, also 
serum sCD26 and DPPIV enzyme activity appear to be 
useful biomarkers. The prognosis of patients with MPM 
can be predicted by DPPIV activity in serum or pleural 
fluid (53).
The relationship between interleukin 6 (IL-6) levels 
and clinical parameters was studied by Nakano et al. in 
25 patients with MPM (54).
 IL-6 mRNA expression in the tumors and serum IL-6 
levels was described also by Bielefeldt-Ohmann et al. (55).
Quite recently among some new serum markers 
differentially expressed in MPM and healthy subjects, have 
been found levels of IL6 statistically different between the 
studied groups (56).
Fitzpatrick et al. suggest involvement of the expression of 
cytokines and cytokine receptors in situ in MMP (57).
Serum TRX-1 (58) and circulating fibrinogen (59) are 
other reported serum biomarkers. 
Combination or panel of serum biomarkers
The combination of multiple markers could be very useful 
to increase sensitivity and specificity in early diagnosis, 
monitoring e screening of MPM rather than the use of 
single markers.
Several panels of biomarkers have been suggested 
as tools for screening and early diagnosis, clinical 
monitoring, prognosis and screening of MPM (60-68). The 
combinations studied are multiple: 80HdG, VEGFbeta and 
SMRPs (60), miR-126, in association with SMRPs (61), serum 
concentrations of SMRP, CA125, and CYFRA21-1 (62), 
combination of serum SMRP and pOPN (27), combination 
of SMRP and miR-103a-3p (63,64), SMRPs, miR-
126 and methylated  thrombomodul in  promoter, 
Met-TM (65), fibulin-3 and SMRP (66), combination of 
miR-132-3 and miR-126 (48), combination of six biomarkers 
(SMRP-pOPN-IL6-vimentin-desmin-HGF) (56). 
Conclusions
For diagnostic and prognostic purposes, to date, SMRP is 
the only biomarker approved by the FDA and suggested by 
several consensuses (66).
In accordance with the most advanced scientific papers 
and the most authoritative guidelines, this biomarker can 
be used, some sensitivity limits, as a diagnostic marker for 
evaluating follow-up therapy and as a prognostic indicator, 
at least in epithelioid mesotheliomas.
Helsinki criteria suggest that SMRP, pOPN, MPF, 
fibulin-3, quantitative miRNA expression and other may be 
useful as a follow-up tool in the treatment of malignancies and 
could be helpful in early clinical diagnosis. A major debate 
is whether early detection can improve treatment outcome. 
Actually no specific recommendations were made regarding 
these biomarkers for screening or other purposes (67).
Studies in recent years show that the use of markers 
panel, using also markers obtained evaluated by different 
approaches based on proteomics technology, greatly 
improves clinical diagnostic performance.
New promising markers are in the study and alone or 
better in combination and will be very helpful in diagnosing 
and monitoring mesothelioma patients.
Recently, a proteomic approach, screening of a large 
number of biomarkers, improves the diagnostic accuracy in 
different types of cancer, including MPM (68-70). 
There are needed additional studies with more enrolled 
patients and better drawing to scrupulously assess the 
diagnostic power of all these biomarkers.
Probably the ongoing studies will allow, in the near 
future, more accurate MPM diagnosis and prognosis, earlier 
detection of MPM and helpful screening of people formerly 
exposed to asbestos (71).
In conclusion, the current status of MPM biomarkers 
is not satisfactory but encouraging due to emerging more 
sensitive and specific non-invasive biomarkers. 
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